We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.76B
AUM Growth
+$192M
Cap. Flow
+$451M
Cap. Flow %
16.36%
Top 10 Hldgs %
46.52%
Holding
86
New
11
Increased
24
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$117M
2
CGEM icon
Cullinan Oncology
CGEM
+$92.4M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$74.2M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$51.3M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$50.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$45.6M
2
RVMD icon
Revolution Medicines
RVMD
+$19M
3
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$16.5M
4
ANAB icon
AnaptysBio
ANAB
+$9.07M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$7.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.65%
2 Financials 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
1
GH Research
GHRS
$1.97B
$216M 7.85%
9,275,158
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.65B
$202M 7.33%
3,180,658
– –
RCUS icon
3
Arcus Biosciences
RCUS
$3.55B
$138M 4.99%
3,398,067
+168,245
+5% +$6.53M
MRUS
4
DELISTED
Merus
MRUS
$131M 4.77%
+4,135,071
New +$117M
PTGX icon
5
Protagonist Therapeutics
PTGX
$8.75B
$125M 4.53%
3,651,759
-250,000
-6% -$7.9M
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.13B
$103M 3.73%
3,289,540
+1,717,762
+109% +$51.3M
RPTX
7
DELISTED
Repare Therapeutics
RPTX
$102M 3.72%
4,858,761
+1,136,363
+31% +$26.8M
RLAY icon
8
Relay Therapeutics
RLAY
$4.14B
$96.1M 3.49%
3,130,605
+1,081,492
+53% +$34.2M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.86B
$85.3M 3.1%
3,003,879
+2,050,000
+215% +$50.5M
CGEM icon
10
Cullinan Oncology
CGEM
$1.05B
$82.9M 3.01%
5,369,459
+4,634,353
+630% +$92.4M
ARGX icon
11
argenx
ARGX
$53.9B
$75.7M 2.75%
216,204
-150,000
-41% -$45.6M
XOMA
12
DELISTED
Xoma
XOMA
$73.6M 2.67%
3,530,543
– –
OLMA icon
13
Olema Pharmaceuticals
OLMA
$1.03B
$69.4M 2.52%
7,411,503
+750,000
+11% +$15.5M
LKFT
14
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$63.8M 2.31%
1,156,393
+36,660
+3% +$1.91M
LXRX icon
15
Lexicon Pharmaceuticals
LXRX
$1.03B
$56.6M 2.05%
14,360,000
– –
AMRN
16
Amarin Corp
AMRN
$293M
$55.5M 2.01%
822,998
+252,639
+44% +$20.9M
EQRX
17
DELISTED
EQRx, Inc. Common Stock
EQRX
$53.6M 1.95%
+7,859,670
New +$74.2M
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.69B
$46M 1.67%
2,099,714
-386,715
-16% -$7.15M
RVMD icon
19
Revolution Medicines
RVMD
$40.3B
$45.6M 1.65%
1,810,549
-674,500
-27% -$19M
FDMT icon
20
4D Molecular Therapeutics
FDMT
$537M
$44M 1.6%
2,005,862
– –
EPIX
21
DELISTED
ESSA Pharma
EPIX
$40.5M 1.47%
2,851,461
– –
RAIN
22
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$38.1M 1.38%
2,957,807
– –
VRDN icon
23
Viridian Therapeutics
VRDN
$2.13B
$37.2M 1.35%
1,879,412
+1,075,286
+134% +$20M
RLMD icon
24
Relmada Therapeutics
RLMD
$545M
$37.1M 1.35%
+1,647,400
New +$36.6M
VSTM icon
25
Verastem
VSTM
$523M
$35M 1.27%
1,421,847
+173,742
+14% +$5.48M
1
2 3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2021 Portfolio in Review

As of Q4 2021, BVF Inc held 86 positions worth $2.76B, up 7.5% from $2.56B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

BVF Inc deployed $451M of net new capital in Q4 2021, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Merus: 4,135,071 shares worth $131M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was argenx, an estimated $45.6M trimmed.

  • BVF Inc's largest Q4 2021 buy was Merus: 4,135,071 shares worth $131M.
  • BVF Inc added most to Cullinan Oncology in Q4 2021, an estimated $92.4M increase.
  • BVF Inc's biggest Q4 2021 reduction was argenx, cutting an estimated $45.6M.
  • BVF Inc fully exited Gritstone bio, Inc. Common Stock in Q4 2021, selling an estimated $16.5M.
  • BVF Inc's ten largest holdings make up 47% of its $2.76B portfolio in Q4 2021.
  • BVF Inc opened 11 new positions and closed 3 in Q4 2021.
  • BVF Inc's portfolio value rose 7.5% quarter-over-quarter to $2.76B.

Based on BVF Inc's 13F filing for Q4 2021, filed 14 Feb 2022.